menu search

Ischemia reperfusion injury therapeutics market revenue to cross usd 3.2 billion by 2031 at a cagr of 3.5%: transparency market research inc.

Increasing prevalence of cardiovascular diseases, increase in geriatric population and surge in awarene...

September 4, 2023, 10:10 am

Cytosorbents announces resignation of chief financial officer alexander d’amico

PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions...

September 1, 2023, 8:43 pm

Why cardinal health (cah) is a top value stock for the long-term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Pre...

September 1, 2023, 11:18 am

cardinal health's (cah) latest launch to enhance neonatal feeding

cardinal Health's (CAH) latest offering is likely to help premature and newborn infants develop the ora...

August 31, 2023, 1:32 pm

Fitness equipment home & gym training market worth usd 157.6261 billion by 2030 globally, at a cagr of 5.86%, says market research future

Fitness Equipment Home & Gym Training Market Research Report: Information By Application (Residential and Commercial), Product Type (...

August 29, 2023, 5:00 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Esperion presents two clear outcomes study late-breakers at european society of cardiology congress 2023

– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% r...

August 26, 2023, 3:00 pm

Biosig (bsgm) grows in arrhythmia care with subscription model

BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments...

August 25, 2023, 11:17 am

Bridgebio pharma to present detailed results from the phase 3 attribute study in patients with transthyretin amyloidosis cardiomyopathy (attr-cm) at european society of cardiology (esc) congress 2023

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

August 24, 2023, 4:01 pm

Biosig ai sciences achieves infrastructure and technology progress in development of generative ai platform for hospitals

Westport, CT, Aug. 24, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology co...

August 24, 2023, 2:30 pm

This new development is helping to send eli lilly and novo nordisk stocks soaring

A new study by Novo Nordisk points to GLP-1 drugs reducing cardiac risks. It's a relevant finding for E...

August 24, 2023, 10:23 am

3 massive new markets could await ozempic, and they might make novo nordisk investors richer

The active ingredient in Ozempic could be useful for quite a few conditions. cardiovascular disease, ce...

August 24, 2023, 5:40 am

Masimo's (masi) pvi favored by study for gdft in elderly patients

Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fl...

August 22, 2023, 2:17 pm

Hca healthcare (hca) favors pullback providing another opportunity

HCA Healthcare, Inc., (HCA) provides health care services company in the United States. The company operates general & acute care hospitals that offer...

August 21, 2023, 8:36 pm

Ozempic just got even better for novo nordisk stock

Ozempic is practically flying off the shelves to treat diabetes and obesity. The drug could also be useful in reducing ...

August 20, 2023, 8:30 am

Newamsterdam pharma: best cardiovascular biotech in 2023

NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating ro...

August 19, 2023, 1:10 pm


Search within

Pages Search Results: